Success Metrics

Active Trials

3(43%)

Phase Distribution

Ph not_applicable

57%

Ph phase_2

14%

Ph phase_1

29%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 1Safety & dosage

2(28.6%)

Phase 2Efficacy & side effects

1(14.3%)

N/ANon-phased studies

4(57.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(7)

Detailed Status

Not yet recruiting4

Recruiting2

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 2

Trials by Phase

Phase 12 (28.6%)

Phase 21 (14.3%)

N/A4 (57.1%)

Trials by Status

recruiting229%

active_not_recruiting114%

not_yet_recruiting457%

Recent Activity

3 active trials

Showing 5 of 7

not_yet_recruitingnot_applicable

Histotripsy in Biliary Tract Cancer

NCT07853690

not_yet_recruitingphase_2

Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma

NCT07766187

recruitingphase_1

A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer

NCT06246968

recruitingphase_1

Evaluation of Circulating Immune Response After Histosonics in Colorectal Cancer (ECHO-CRC)

NCT07361107

active_not_recruitingnot_applicable

Histotripsy (HistoSonics®) for Liver Tumours

NCT06579833

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT07853690Not Applicable

Histotripsy in Biliary Tract Cancer

Not Yet Recruiting

NCT07766187Phase 2

Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma

Not Yet Recruiting

NCT06246968Phase 1

A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer

Recruiting

NCT07361107Phase 1

Evaluation of Circulating Immune Response After Histosonics in Colorectal Cancer (ECHO-CRC)

Recruiting

NCT06579833Not Applicable

Histotripsy (HistoSonics®) for Liver Tumours

Active Not Recruiting

NCT07180706Not Applicable

To Evaluate the Safety and Efficacy of Histotripsy for the Symptom Relief of Inoperable Abdominal Tumors

Not Yet Recruiting

NCT07063771Not Applicable

Safety and Clinical Efficacy of Histotripsy for Liver Cancers Adjacent to Major Intrahepatic Vessels

Not Yet Recruiting

All 7 trials loaded

Drug Details

Intervention Type: DEVICE
Total Trials: 7